TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
GANX

Gain Therapeutics Inc

Healthcare · Biotechnology

1.80$ +0.0% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

Gain Therapeutics Inc (GANX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 15 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet GANX
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
14 19 15 19 14 12 12 9.8 11 23 19 15
13 18 14 19 14 12 11 9.3 11 22 18 15
4.3 12 11 17 12 10 9.1 6.7 8.8 21 17 13
12 17 13 17 12 10 9.1 6.7 8.8 21 17 13
0.1 0.2 0.2 0.3 0.4 0.8 0.9 1.4 0.8 0.8 1.0 0.2
0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1
6.8 6.0 5.9 7.4 5.5 4.8 5.8 6.1 5.1 4.3 4.7 4.1
5.8 4.9 5.0 6.5 4.6 3.9 5.0 5.2 4.2 3.4 3.9 3.4
0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.2
1.4 1.3 1.4 2.0 1.1 0.9 2.2 2.7 1.6 0.8 1.5 1.2
0.4 0.4 0.4 0.4 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.2
7.3 13 8.6 12 8.9 7.3 5.8 3.7 5.9 19 14 11
-56 -61 -65 -73 -77 -81 -86 -92 -97 -101 -107 -112
13 16 18 19 27 27 29 30 35 33 42 43

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?